Novyra Pharmachem PE ratio, market cap and valuation
BSE: 519353Agricultural Food & other ProductsSmall Cap
Last close ₹8.50down ₹0.21 (2.41%)
Share price at the BSE close on 13 Oct 2026. Previous close ₹8.71.
52-week range of traded prices to 13 Oct 2026
₹6.47Low, 13 Oct 2025₹16.55High, 23 Mar 2026
- Under BSE's graded surveillance, stage 0, on the list for 22 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹5.38 Cr4,706th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 8 Aug 2026
- 9.1
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 14 Aug 2026
- −166.3%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 14 Aug 2026
- −906.7%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 8 Aug 2026
- 0.00
- Volume, BSEVolume. Shares traded on the last trading day.
- 100
Novyra Pharmachem PE ratio and valuation against its own history
Each ratio on 13 Oct 2026. A window's median is shown once it holds most of its trading days. The PE ratio is the market cap over the profit of the last twelve months.
- Price to earningsPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.Loss, last twelve months
- Price to bookPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.9.09today
- Price to salesPrice to sales, trailing. Market cap divided by the revenue of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly): what investors pay for each rupee of a year's sales.2.89today
- EV to EBITDAEnterprise value to EBITDA. Market cap plus borrowings less cash and bank balances, divided by operating profit before depreciation (revenue less operating expenses, without other income and one-off items) over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly): what the whole business costs against the profit its operations make. Lease liabilities are not counted: the results filings do not state them.Operating loss, last twelve months
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.0.00%today
- Earnings yieldEarnings yield. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) as a percentage of market cap, the P/E turned upside down.−99.78%today
Dividend yield is in per cent. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
How each ratio is worked out, with today's figures
The twelve months: Filed 14 AugThe balance sheet: Filed 8 Aug
- Price to book =Market cap÷Net worthNet worth. Shareholders' equity in the latest balance sheet.₹0.59 Cr
- Price to sales =Market cap÷Revenue, last twelve monthsRevenue, last twelve months. Revenue from operations over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly).₹1.86 Cr
- Enterprise value =Market cap+BorrowingsBorrowings. Total borrowings in the latest balance sheet.₹0.00 Cr−CashCash. Cash and bank balances in the latest balance sheet.₹0.15 Cr
- Market cap =Close×Shares in issueShares in issue. The shares in issue in the latest shareholding filing.63,30,000at 30 Jun 2026
- Net profit, last twelve monthsNet profit, last twelve months. Net profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly).
- −₹5.37 Cr
- Operating profit, last twelve monthsOperating profit, last twelve months. Profit before depreciation, interest and tax over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly).
- −₹5.34 Cr
Standalone accounts, the twelve months to Jun 2026, balance sheet at Mar 2026, ₹ crore.Novyra Pharmachem financials ›
Novyra Pharmachem valuation at each year end
On the last trading day of each March, the month the company's year ends.
| Ratio | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2026 |
|---|---|---|---|---|
| Market cap (₹ crore)Market capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. | 2.96 | 6.14 | 2.11 | 9.48 |
| Price to earningsPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. | Earlier quarters restated in the year | 105.2 | Loss | Loss |
| Price to bookPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. | 0.0 | 1.0 | 0.4 | 1.6 |
| Price to salesPrice to sales, trailing. Market cap divided by the revenue of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly): what investors pay for each rupee of a year's sales. | 0.4 | 40.9 | 56.4 | 286.3 |
| EV to EBITDAEnterprise value to EBITDA. Market cap plus borrowings less cash and bank balances, divided by operating profit before depreciation (revenue less operating expenses, without other income and one-off items) over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly): what the whole business costs against the profit its operations make. Lease liabilities are not counted: the results filings do not state them. | Operating loss | 182.2 | Operating loss | Operating loss |
| Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. | 0.00% | 0.00% | 0.00% | 0.00% |
| Earnings yieldEarnings yield. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) as a percentage of market cap, the P/E turned upside down. | Earlier quarters restated in the year | 1.0% | −8.1% | −0.7% |
A ratio that does not exist on the day says why in its cell.
Novyra Pharmachem market cap, since Jun 2017
The last trading day of each month.
Market cap, ₹ crore
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price.
Earnings per share, book value and enterprise value
From the close on 13 Oct 2026, with the last twelve months' results.
- Enterprise valueEnterprise value. Market cap plus borrowings less cash and bank balances: what it would cost to buy the whole business, its debts included.
- ₹5.23 Cr
- Earnings per shareEarnings per share, trailing. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) divided by the number of shares in issue.
- −₹8.48
- Book value per shareBook value per share. Net worth, the company's assets less everything it owes, divided by the number of shares in issue.
- ₹0.94
- Dividends, last 12 monthsDividends per share, last 12 months. Dividends per share with an ex-date in the last twelve months, restated for any split or bonus since.
- None
- Public's market capPublic's market cap. The market value of the shares held by everyone other than the promoters, the group that set up or controls the company.
- ₹4.13 Cr
Against Tea & Coffee
28 listed companies in Tea & Coffee, each priced on its last trading day; Novyra Pharmachem is 27th among them by market cap. Each median leaves out Novyra Pharmachem itself and takes the other companies that have the figure.
- Industry median P/EIndustry median trailing P/E. The middle trailing P/E of the listed companies in the same industry that have one, leaving out the company itself and any P/E above 200.
- 12.6Across 13 other companies
- Industry median P/BIndustry median P/B. The middle P/B of the listed companies in the same industry that have one, leaving out the company itself.
- 0.6Across 26 other companies
- Industry median EV/EBITDAIndustry median EV/EBITDA. The middle EV/EBITDA of the listed companies in the same industry that have one, leaving out the company itself.
- 15.2Across 18 other companies
- Industry median dividend yieldIndustry median dividend yield. The middle dividend yield of the listed companies in the same industry that paid a dividend in the last twelve months, leaving out the company itself.
- 0.78%Across 11 other companies